This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Jul;12(7):615-6.

doi: 10.1016/S1470-2045(11)70158-9. Epub 2011 Jun 16.

Oesophageal cancer: who needs neoadjuvant therapy?

Thomas N Walsh¹

Affiliations

PMID: 21684208
DOI: 10.1016/S1470-2045(11)70158-9

Comment

Oesophageal cancer: who needs neoadjuvant therapy?

Thomas N Walsh. Lancet Oncol. 2011 Jul.

. 2011 Jul;12(7):615-6.

doi: 10.1016/S1470-2045(11)70158-9. Epub 2011 Jun 16.

Author

Thomas N Walsh¹

Affiliation

¹ Royal College of Surgeons in Ireland/Conolly Hospital, Blanchardstown, Ireland. tnwalsh@indigo.ie

PMID: 21684208
DOI: 10.1016/S1470-2045(11)70158-9

No abstract available

PubMed Disclaimer

Comment on

Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis.
Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A, Gebski V; Australasian Gastro-Intestinal Trials Group. Sjoquist KM, et al. Lancet Oncol. 2011 Jul;12(7):681-92. doi: 10.1016/S1470-2045(11)70142-5. Epub 2011 Jun 16. Lancet Oncol. 2011. PMID: 21684205

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Medical
- MedlinePlus Health Information